Who is sponsoring UV1-hTERT2012L?

UV1-hTERT2012L is sponsored by Ultimovacs ASA.

What condition does UV1-hTERT2012L study?

UV1-hTERT2012L studies Non-small Cell Lung Cancer.

What drugs are being tested in UV1-hTERT2012L?

Interventions: UV1 synthetic peptide vaccine and GM-CSF.

What is the status of UV1-hTERT2012L?

UV1-hTERT2012L is currently COMPLETED.

Last reviewed 2024-12-16 · How we verify

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (UV1-hTERT2012L)

NCT01789099 PHASE1, PHASE2 COMPLETED

In this study, up to 21 patients with lung cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels. The safety and tolerability of UV1 as well as immunological response will be assessed. The purpose of this study is to select a biological dose of peptides for further clinical trials. Study recruitment completed at 6 patients in every dose level. The main study treatment phase of this study is completed and will be reported separately. Follow-up is ongoing

Details

Lead sponsor	Ultimovacs ASA
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	18
Start date	Mon Apr 08 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Non-small Cell Lung Cancer

Interventions

UV1 synthetic peptide vaccine and GM-CSF

Countries

Norway